Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors

Seminars in Nuclear Medicine

Volumn 41, Issue 5, 2011, Pages 334-344

  Mairs, Rob J ^a   Boyd, Marie ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ASTATINE 211; BORTEZOMIB; DISULFIRAM; HISTONE DEACETYLASE INHIBITOR; META ASTATOBENZYLGUANIDINE AT 211; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; NONHUMAN; REVIEW;

3-IODOBENZYLGUANIDINE; ANIMALS; BYSTANDER EFFECT; CELL LINE, TUMOR; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; NEUROENDOCRINE TUMORS;

EID: 79960930191     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.03.004     Document Type: Review

References (144)

1. Smets LA, Loesberg C, Janssen M, et al: Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SKNSH cells. Cancer Res 49:2941-2944, 1989 (Pubitemid 19148630)
2. Wafelman AR, Hoefnagel CA, Maes RA, et al: Radio-iodinated MIBG: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21:545-559, 1994 (Pubitemid 24189419)
3. Gaze MN, Huxham IM, Mairs RJ, et al: Intracellular localization of mIBG in human neuroblastoma cells by electron spectroscopic imaging. Int J Cancer 47:875-880, 1991
4. Mairs RJ, Cunningham SH, Russell J, et al: No-carrier-added 131I-mIBG: evaluation of a novel preparation of a therapeutic radiopharmaceutical. J Nucl Med 36:1088-1095, 1995
5. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20:195-199, 2005
6. Wangberg B, Muth A, Khorram-Manesh A, et al: Malignant pheochromocytoma in a population-based study. Ann N Y Acad Sci 1073:512-516, 2006
7. Matthay KK, Tan JC, Villablanca JG, et al: Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500-506, 2006 (Pubitemid 46630470)
8. Voute PA, van der Kleij AJ, De Kraker J, et al: Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 31A:596-600, 1995
9. Diehl M, Fußhoeller G, Menzel C, et al: Hyperbaric oxygen to intensify 131-I-MIBG therapy in refractory neuroblastoma stage 4. Nuklearmedizin 6:N77-N80, 2004
10. 131I- metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98:239-248, 2003
11. Gaze MN, Wheldon TE, O'Donoghue JA, et al: Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high-dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 31A:252-256, 1995
12. Mangner JT, Wu J-L, Wieland DM: Solid-phase exchange radioiodination of aryl iodides: facilitation by ammonium sulfate. J Org Chem 47:1484-1488, 1982
13. 131I]iodobenzylguanidine. Appl Radiat Isot 44:621-628, 1993
14. 131I]iodobenzylguanidine in patients. Cancer Res 47:6147-6149, 1987
15. 131I]MIBG in nude mice bearing SKNSH human neuroblastoma xenografts: effect of specific activity. Br J Cancer 73:1171-1177, 1996
16. Babich JW, Graham W, Fischman AJ: Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells. Eur J Nucl Med 24:538-543, 1997 (Pubitemid 27239213)
17. Vaidyanathan G, Affleck DJ, Alston KL, et al: A tin precursor for the synthesis of no-carrier-added [*I]MIBG and [211At] MABG. J Label Compd Rad 50:177-182, 2007 (Pubitemid 46750664)
18. 123I] MIBG. J Label Compd Rad 42:653-661, 1999
19. 125I]iodobenzylguanidine on the human neuroblastoma cell lines SKNSH and SKN-LO. Cancer Res 48:2993-2997, 1988
20. 123I]MIBG in rats. Nucl Med Commun 9:663-667, 1988
21. Verberne HJ, de Bruin K, Habraken JBA, et al: No-carrier-added versus carrier-added 123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity. Eur J Nucl Med 33:483-490, 2006
22. 131I]MIBG in xenografted BALB/c nu/nu mice, in Evans AE, Biedler JL, Brodeur GM, et al (eds):Advances in Neuroblastoma Research (ed 4). New York, Wiley-Liss, 1994, pp 446-453
23. Mairs RJ, Russell J, Cunningham SH, et al: Enhanced tumor uptake and in vitro radiotoxicity of no-carrier-added 131I-MIBG: implications for the radiotherapy of neuroblastoma. Eur J Cancer 31:576-581, 1995
24. 131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Lett Drug Des Disc 1:50-57, 2004
25. 123/131I-MIBG on efficacy, pharmacokinetics and tissue distribution. Cancer Biother Radiopharm 25:299-308, 2010
26. Fredrikson M, Hursti TJ, Steineck G, et al: Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 70:642-645, 1994 (Pubitemid 24305590)
27. 131I-meta-iodobenzylguanidine. Eur J Nucl Med 14:337-340, 1988
28. Bongers V, de Klerk JMH, Zonnenberg BA, et al: Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors. J Nucl Med 38:1024-1026, 1997
29. Dahllof G, Borgstrom P, Lundell G, et al: Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma. Oral Med Oral Surg Oral Pathol Oral Radiol Endod 92:420-423, 2001 (Pubitemid 33601740)
30. Mairs RJ, Zalutsky MR: New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. Br J Cancer 72:250, 1995
31. 123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 27:302-307, 2000
32. 123I]iodobenzylguanidine in clinical studies II. Eur J Nucl Med 28:941, 2001
33. 123I]mIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun21:437-440, 2000
34. James O, Coleman RE: Radioiodinated MIBG in paraganglioma and pheochromocytoma: previous results and early experiences using nocarrier- added MIBG. Nucl Med Biol 35:S1:63-S1:76, 2009
35. Humm JL: Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27:1490-1497, 1986
36. Gaze MN, Mairs RJ, Boyack SM, et al: 131-I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 64:1048-1052, 1992 (Pubitemid 23006141)
37. Zalutsky MR, Vaidyanathan G: Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Curr Pharm Des 6:1433-1455, 2000
38. Zalutsky MR, Reardon DA, Akabani G, et al: Clinical experience with α-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49:30-38, 2008
39. Vaidyanathan G, Affleck DJ, Alston KL, et al: A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem 15:3430-3436, 2007 (Pubitemid 46529264)
40. 211At] astatobenzylguanidine on human neuroblastoma cells. Cancer Res 54:5414-5419, 1994
41. Vaidyanathan G, Strickland DK, Zalutsky MR: Meta-[211At] astatobenzylguanidine: further evaluation of a potential therapeutic agent. Int J Cancer 57:908-913, 1994
42. Cunningham SH, Mairs RJ, Wheldon TE, et al: Radiotoxicity to neuroblastoma cells and spheroids of beta-, alpha- and Auger electron-emitting conjugates of benzylguanidine. Br J Cancer 77:2061-2068, 1998
43. Boyd M, Mairs RJ, Keith WN, et al: An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med 6:937-947, 2004 (Pubitemid 40228109)
44. Fullerton NE, Boyd M, Ross SC, et al: Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. J Med Chem 1:611-618, 2005
45. Boyd M, Ross SC, Dorrens J, et al: Radiation induced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha, beta- and Auger electron emitting radionuclides. J Nucl Med 47:1007-1015, 2006 (Pubitemid 46939954)
46. McCarthy H, Worthington J, Barrett E, et al: p21(WAF-1)-mediated transcriptional targeting of iNOS gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 14:246-255, 2007 (Pubitemid 46152628)
47. Boyd M, Mairs SC, Stevenson K, et al: Transfectant mosaic spheroids: a new model for the evaluation of bystander effects in experimental gene therapy. J Gene Med 4:567-576, 2002 (Pubitemid 40268383)
48. Mothersill C, Seymour CB: Radiation induced bystander effects: past history and future directions. Radiat Res 155:759-767, 2001 (Pubitemid 32494601)
49. Mothersill C, Seymour CB: Radiation-induced bystander effects: implications for cancer. Nat Rev Cancer 4:158-164, 2004 (Pubitemid 38198744)
50. Lyng FM, Seymour CB, Mothersill C: Early events in the apoptotic cascade initiated in cells treated with medium from the progeny of irradiated cells. Radiat Prot Dosimetry 99:169-172, 2002
51. Lorimore SA, Wright EG: Radiation-induced genomic instability and bystander effects: related inflammatory-type responses to radiation-induced stress and injury? a review. Int J Radiat Biol 79:15-25, 2003 (Pubitemid 36140233)
52. Morgan WF: Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionising radiation? Oncogene 22:7094-7099, 2003
53. Little JB: Genomic instability and bystander effects: a historical perspective. Oncogene 22:6978-6987, 2003
54. Carlsson J, Aronsson EF, Hietala S-O, et al: Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66:107-117, 2003 (Pubitemid 36321806)
55. Bishayee A, Hill HZ, Stein D, et al: Free radical-initiated and gap junction-mediated bystander effect due to nonuniform distribution of incorporated radioactivity in a three-dimensional tissue culture model. Radiat Res 155:335-344, 2001 (Pubitemid 32125985)
56. Xue LY, Butler NJ, Makrigiorgos GM, et al: Bystander effect produced by radiolabelled tumour cells in vivo. Proc Natl Acad Sci U S A 99:13765-13770, 2002 (Pubitemid 35215455)
57. Kassis AI: In vivo validation of the bystander effect. Hum Exp Toxicol 23:71-73, 2004
58. Mothersill C, Seymour CB: Medium from irradiated human epithelial cells but not human fibroblasts reduced clonogenic survival of unirradiated cells. Int J Radiat Biol 71:421-427, 1997 (Pubitemid 27187398)
59. Seymour CB, Mothersill C: Relative contribution and targeted cell killing to the low-dose region of the radiation dose-response curve. Radiat Res 153:508-511, 2000 (Pubitemid 30252597)
60. Belyakov OV, Malcolmson AM, Folkard M, et al: Direct evidence for a bystander effect of ionizing radiation in primary human fibroblasts. Br J Cancer 84:674-679, 2001 (Pubitemid 32239002)
61. O'Donoghue JA, Bardies M, Wheldon TE: Relationships between tumour size and curability for uniformly targeted therapy with betaemitting radionuclides. J Nucl Med 36:1902-1909, 1995
62. Armour A, Cunningham SH, Gaze MN, et al: The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 75:470-476, 1997 (Pubitemid 27085284)
63. Smets LA, Janssen M, Rutgers M, et al: Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical miodo- benzylguanidine in SKNSH neuroblastoma and PC-12 pheochromocytoma cells.Int J Cancer 48:609-615, 1991
64. Montaldo PG, Carbone R, Ponzoni M, et al: γInterferon increases metaiodobenzylguanidine incorporation and retention in humanneuroblastoma cells. Cancer Res 52:4960-4964, 1992
65. Montaldo PG, Raffaghello L, Guarnaccia F, et al: Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer 67:95-100, 1996 (Pubitemid 26236074)
66. Hopfner M, Sutter AP, Huether A, et al: A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive anti-proliferative effects of interferon-gamma and meta-iodobenzylguanidine. BMC Cancer 4:23-37, 2004
67. Mairs RJ, Wheldon TE: Experimental tumour therapy with targeted radionuclides in multicellular tumour spheroids, in Hagen U, Harder D, Jung H,et al (eds): Radiation Research 1895-1995; Congress Proceedings, 1996, Vol 2. Wurtzburg: Universitatsdruckerei, H. Sturtz AG, 1996, pp 819-826
68. Meco D, Lasorella A, Riccardi A, et al: Influence of cisplatin and doxorubicin on I-125-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 35:1227-1234, 1999 (Pubitemid 29359183)
69. 3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer 18:143-149, 2011
70. Rothenberg ML: Topoisomerase I inhibitors: review and update.Ann Oncol 8:837-855, 1997
71. Vassal G, Pondarré C, Capelli C, et al: DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer 33:2011-2015, 1997 (Pubitemid 28123445)
72. Nitschke R, Parkhurst J, Sullivan J, et al: Topotecan in pediatric patients with recurrent and progressive solid tumours: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318, 1998 (Pubitemid 28483337)
73. 131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma. Cancer Lett 228:221-227, 2005
74. Miyamoto S, Huang TT, Wuerzberger-Davis S, et al: Cellular and molecular responses to topoisomerase I poisons: exploiting synergy for improved radiotherapy. Ann N Y Acad Sci 922:274-292, 2000 (Pubitemid 32050260)
75. Mattern MR, Hofmann GA, McCabe FL, et al: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK and F 104864). Cancer Res 51:5813-5816, 1991
76. Boscia RE, Korbut T, Holden SA, et al: Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSaIIC fibrosarcoma in vivo. Int J Cancer 53:118-123, 1993 (Pubitemid 23018433)
77. Hennequin C, Giocanti N, Balosso J, et al: Interaction of ionising radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 54:1720-1728, 1994
78. Marchesini R, Colombo A, Caserini C, et al: Interaction of ionizing radiation with topotecan in two human cell lines. Int J Cancer 66:342-346, 1996 (Pubitemid 26166196)
79. Lamond JP, Wang M, Kinsella TJ, et al: Concentration and timing dependence enhancement between topotecan, a topoisomerase I inhibitor and ionising radiation. Int J Radiat Oncol Biol Phys 36:361-368, 1996 (Pubitemid 26359462)
80. Kohara H, Tabata M, Kiura K, et al: Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res 8:287-292, 2002 (Pubitemid 34101490)
81. 131I]meta-iodobenzylguanidine and topotecan in combination. Br J Radiol 81:S28-35S, 2008
82. Dubois SG, Messina J, Maris JM, et al: Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 22:2452-2460, 2004 (Pubitemid 41115404)
83. Kramer K, Kushner BH, Cheung N-KV: Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol 25:601-605, 2003 (Pubitemid 36959419)
84. Yanik GA, Levine JE, Matthay KK, et al: Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142-2149, 2002 (Pubitemid 34408806)
85. Chalmers AC: The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 89:23-40, 2009
86. De Murcia JM, Niedergang C, Trucco C, et al: Requirement of poly-(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.Proc Natl Acad Sci U S A 94:7303-7307, 1997 (Pubitemid 27345310)
87. Albert JM, Cao C, Kim KW, et al: Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13:3033-3042, 2007 (Pubitemid 46849580)
88. Dungey FA, Loeser DA, Chalmers AJ: Replication-dependent radiosensitisation of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72:1188-1197, 2008
89. Smith LM, Willmore E, Austin CA, et al: The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res 11:8449-8457, 2005 (Pubitemid 41746960)
90. Woon EC, Threadgill MD: Poly(ADP-ribose)polymerase inhibition: where now? Curr Med Chem 12:2373-2392, 2005
91. Chalmers AJ: Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin Oncol 16:29-39, 2004
92. Brock WA, Milas L, Bergh S, et al: Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205:155-160, 2004 (Pubitemid 38230122)
93. Calabrese CR, Almassy R, Barton S, et al: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase- 1 inhibitor AG14361. J Natl Cancer Inst 96:56-67, 2004 (Pubitemid 38180960)
94. Dungey FA, Loser DA, Chalmers AJ: Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72:1188-1197, 2008
95. Yung TM, Sato S, Satoh MS: Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1-topoisomerase I interaction. J Biol Chem 279:39686-39696, 2004 (Pubitemid 39258237)
96. Malanga M, Althaus FR: Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J Biol Chem 279:5244-5248, 2004 (Pubitemid 38220543)
97. Beidler DR, Chang JY, Zhou BS, et al: Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56:345-353, 1996 (Pubitemid 26026364)
98. Calabrese CR, Batey MA, Thomas HD, et al: Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 9:2711-2718, 2003 (Pubitemid 36842117)
99. Delaney CA, Wang LZ, Kyle S, et al: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6:2860-2867, 2000 (Pubitemid 30482128)
100. Bowman KJ, Newell DR, Calvert AH, et al: Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84:106-112, 2001 (Pubitemid 32102513)
101. Tentori L, Portarena I, Graziani G: Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res45:73-85, 2002 (Pubitemid 35425647)
102. Beneke S, Diefenbach J, Bürkle A, et al: Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 111:813-818, 2004 (Pubitemid 39096229)
103. Graziani G, Szabo C: Clinical perspectives of PARP inhibitors.Pharmacol Res 52:109-118, 2005 (Pubitemid 40725605)
104. Jagtap P, Szabo C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440, 2005 (Pubitemid 40704125)
105. Adams J, Boyd M: Development of the proteasome inhibitor, PS-341. Oncologist 7:9-16, 2002
106. Richardson P, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003 (Pubitemid 36741588)
107. Blaney SM, Bernstein M, Neville K, et al: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22:4804-4809, 2004
108. Desai SD, Liu LF, Vasquez-Abad D, et al: Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumour drug camptothecin. J Biol Chem 272:24159-24164, 1997 (Pubitemid 27418613)
109. Pajonk F, van Ophoven A, Weissenberger C, et al: The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer 5:76, 2005
110. Goktas S, Baran Y, Ural AU, et al: Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology 75:793-798, 2010
111. Labussière M, Pinel S, Vandamme M, et al: Radiosensitizing properties of bortezomib depend on therapeutic schedule. Int J Radiat Oncol Biol Phys 79:892-900, 2011
112. Brans B, Bodei L, Giammarile F, et al: Clinical radionuclide therapy dosimetry: the quest for the holy gray. Eur J Nucl Med 34:772-786, 2007 (Pubitemid 46669368)
113. Toyokuni S, Okamoto K, Yodoi J, et al: Persistent oxidative stress in cancer. FEBS Lett 358:1-3, 1995
114. Kawanishi S, Hiraku Y, Pinlaor S, et al: Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 387:365-372, 2006
115. Oberley TD, Oberley LW: Antioxidant enzyme levels in cancer. Histol Histopathol 12:525-535, 1997 (Pubitemid 27240324)
116. Marengo B, Raffaghello L, Pistoia V, et al: Reactive oxygen species: biological stimuli of neuroblastoma cell response. Cancer Lett 228:111-116, 2005 (Pubitemid 41188432)
117. Marengo B, De Ciucis C, Ricciarelli R, et al: PKCδ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage. PLoS ONE 6:e14661:1-12, 2011
118. Trachootham D, Alexandre J, Huang P, et al: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Natl Rev 8:579-591, 2009
119. Forman HJ, York JL, Fisher AB, et al: Mechanism for the potentiation of oxygen toxicity by disulfiram. J Pharmacol Exp Ther 212:452-455, 1980 (Pubitemid 10016550)
120. Chen D, Cui QC, Yang H, et al: Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66:10425-10433, 2006 (Pubitemid 44799763)
121. Schreck R, Meier B, Mannel DN, et al: Dithiocarbamates as potent inhibitors of nuclear factor B activation in intact cells. J Exp Med 175:1181-1194, 1992
122. Scribner DR, Benbrook DM: Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol 85:223-225, 2002
123. Fernandez PC, Machado JJ, Heussler VT, et al: The inhibition of NF-B activation pathways and the induction of apoptosis by dithiocarbamates in T cells are blocked by the glutathione precursor N-acetyl-l-cysteine. Biol Chem 380:1383-1394, 1999 (Pubitemid 30021360)
124. Karin M: Nuclear factor-kB in cancer development and progression. Nature 441:431-436, 2006
125. Liu GY, Frank N, Bartsch H, et al: Induction of apoptosis by thiuram-disulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFB, c-fos/c-jun, and p53 proteins. Mol Carcinogen 22:235-246, 1998 (Pubitemid 28394985)
126. Cen D, Gonzalez RI, Buckmeier JA, et al: Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 1:197-204, 2002
127. Wang C-Y, Cusack JCJ, Liu R, et al: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-B. Nat Med 5:412-417, 1999 (Pubitemid 29180579)
128. Cusack JCJ, Liu R, Baldwin AS Jr, et al: Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-B activation. Cancer Res 60:2323-2330, 2000 (Pubitemid 30262414)
129. Yakisich JS, Sidén Å, Eneroth P, et al: Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem Biophys Res Commun 289:586-590, 2001 (Pubitemid 33143819)
130. Canty TG, Boyle EM, Farr A, et al: Oxidative stress induces NF-kappaB nuclear translocation without degredation of IkappaBalpha. Circulation 100:11361-11364, 1999
131. Houtgraaf JH, Versmissen J, van der Giessen WJ, et al: A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med 7:165-172, 2006 (Pubitemid 44292065)
132. Bucher N, Britten CD: G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 98:523-528, 2008 (Pubitemid 351214533)
133. Zabludoff SD, Deng C, Grondine MR, et al: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966, 2008
134. Oza V, Ashwell S, Brassil P, et al: Discovery of a novel class of triazolones as checkpoint kinase inhibitors: hit to lead exploration. Bioorg Med Chem Lett 20:5133-5138, 2010
135. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128:683-692, 2007 (Pubitemid 46273572)
136. Novak P, Jensen TJ, Garbe JC, et al: Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 69:5251-5260, 2009
137. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784, 2006 (Pubitemid 44348499)
138. O'Connor OA, Heaney ML, Schwartz L, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173, 2006 (Pubitemid 46630509)
139. Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51, 2006 (Pubitemid 43054973)
140. Cerna D, Camphausen K, Tofilon PJ: Histone deacetylation as a target for radiosensitization. Curr Top Dev Biol 73:173-204, 2006 (Pubitemid 43878133)
141. Banuelos CA, Banath JP, MacPhail SH, et al: Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res 13:6816-6826, 2007 (Pubitemid 350206820)
142. Teitz T, Wei T, Valentine MB, et al: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529-535, 2000 (Pubitemid 30305902)
143. Jaboin J, Wild J, Hamidi H, et al: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62:6108-6115, 2002 (Pubitemid 35244459)
144. Coffey DC, Kutko MC, Glick RD, et al: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61:3591-3554, 2001